<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269695</url>
  </required_header>
  <id_info>
    <org_study_id>B7581002</org_study_id>
    <secondary_id>2017-002108-28</secondary_id>
    <secondary_id>BUILD UC</secondary_id>
    <nct_id>NCT03269695</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.</brief_title>
  <official_title>A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if PF-06687234 is effective and safe as add-on&#xD;
      therapy to infliximab in subjects with active ulcerative colitis who are not in remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, double-blind, placebo-controlled, parallel group study in subjects with&#xD;
      active ulcerative colitis and a non-remission (partial) response to infliximab. All enrolled&#xD;
      subjects must have been on infliximab for a minimum of 14 weeks with last dose 8 weeks prior&#xD;
      to the date of randomization. Subjects will be randomly assigned to 1 of 2 treatment arms&#xD;
      (PF-06687234 or placebo) administered subcutaneously every week for a total of 12 doses.&#xD;
      Blood, stool and tissue samples will be collected at various time points throughout the study&#xD;
      to evaluate efficacy, safety, tolerability, pharmacokinetics and immunogenicity. Duration of&#xD;
      participation for subjects will be approximately 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The Sponsor changed R&amp;D strategy and priority.&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">January 7, 2021</completion_date>
  <primary_completion_date type="Actual">January 7, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in Clinical Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission defined by a modified Mayo Score with an endoscopic subscore less than or equal to 1, stool frequency subscore less than or equal to 1 and rectal bleeding subscore = 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with endoscopic improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>Endoscopic improvement defined as decrease of 1 point in Mayo endoscopy score or an absolute endoscopy score of 1 or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline at Week 12 in Geboes histology score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Mean change from baseline at Week 12 in Geboes score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a clinical response</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical response defined with a decrease from baseline of at least 3 points in total Mayo score with at least 30% change, accompanied by at least one point decrease or absolute score of 0 or 1 in rectal bleeding subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with change from baseline in partial Mayo Score of 2 or less with no individual subscore &gt;1</measure>
    <time_frame>Weeks 2, 4, 6, 8, 12</time_frame>
    <description>Proportion of subjects with partial Mayo score &lt;=2 with no individual subscore of &gt; 1 at Week 2, 4, 6, 8 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of PF 06687234</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Measure serum concentration of PF-06687234 at baseline, Week 1, 3, 7, 11, 12, and 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the development of HAFAs and Nabs against PF 06687234.</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>Measure HAFA and neutralizing antibody against IL10 at screen, baseline, Week 3, 7, 11, 12, and 16</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>PF-06687234</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PF-06687234 matched Placebo SC QW x 12 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06687234</intervention_name>
    <description>SC QW</description>
    <arm_group_label>PF-06687234</arm_group_label>
    <other_name>Investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC QW</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PF-06687234 matched placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and/or female subjects 18 years to 75 years of age and weight &gt; 40 kg at the time&#xD;
             of informed consent.&#xD;
&#xD;
          -  A diagnosis of active UC (histologic) for 4 months.&#xD;
&#xD;
          -  Subjects with active UC as defined by (via screening endoscopy) a total Mayo Score of&#xD;
             4 or more but 9 or less and an endoscopic subscore of 2.or more.&#xD;
&#xD;
          -  UC extending at least 15 cm proximal to the anal verge at the time of the screening&#xD;
             endoscopy.&#xD;
&#xD;
          -  Must be on a stable dose 5-10 mg/kg of Remicade, Inflectra, or Remsima for a minimum&#xD;
             of 14 weeks with no anticipation of need for change in infliximab treatment regimen&#xD;
             throughout the study&#xD;
&#xD;
          -  Male subjects able to father children and female subjects of childbearing potential&#xD;
             and at risk for pregnancy must agree to use two methods of contraception (at least one&#xD;
             of which is considered as highly effective) throughout the study and until the Week 16&#xD;
             visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a diagnosis or documented history of total colectomy and/or pouchitis,&#xD;
             indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis,&#xD;
             radiation colitis, and diverticular disease associated with colitis, or clinical&#xD;
             findings suggestive of Crohn's disease.&#xD;
&#xD;
          -  Subjects need for surgery or with major elective surgery scheduled during the study.&#xD;
&#xD;
          -  Subjects with extensive colitis for at least 8 years who have not had a colonoscopy&#xD;
             with surveillance biopsies within 2 years prior to baseline.&#xD;
&#xD;
          -  Subjects with history of or at screening endoscopy, biopsy documented colonic&#xD;
             dysplasia or neoplasia.&#xD;
&#xD;
          -  Subjects who require infliximab dosing interval other than every 6 weeks or every 8&#xD;
             weeks.&#xD;
&#xD;
          -  Subjects displaying clinical signs of fulminant colitis or toxic megacolon, with&#xD;
             primary sclerosing cholangitis, known colonic stricture, history of colonic, small&#xD;
             bowel obstruction or resection, with history of or current colonic or small bowel&#xD;
             stoma.&#xD;
&#xD;
          -  Cyclic neutropenia, thrombocytopenia, lymphopenia, leukopenia or history of chronic&#xD;
             anemia.&#xD;
&#xD;
          -  Presence of active enteric infection.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) based on documented history with&#xD;
             positive serological test, or positive HIV serologic test.&#xD;
&#xD;
          -  Presence of transplanted organ.&#xD;
&#xD;
          -  Anticipated need for any live vaccine.&#xD;
&#xD;
          -  Class III or Class IV heart failure.&#xD;
&#xD;
          -  Acute coronary syndrome and any history of cerebrovascular disease.&#xD;
&#xD;
          -  Subjects with current, or a history of QT prolongation.&#xD;
&#xD;
          -  Subjects receiving the following therapies within the designated time period:&#xD;
&#xD;
               -  &gt;9 mg/day of oral budesonide or &gt;20 mg/day of prednisone or equivalent within 2&#xD;
                  weeks prior to baseline.&#xD;
&#xD;
               -  IV, IM or topical (rectal) treatment of 5-ASA or corticosteroid enemas within 2&#xD;
                  weeks prior to baseline.&#xD;
&#xD;
               -  Anti integrin inhibitors within 14 weeks prior to baseline.&#xD;
&#xD;
               -  Any use of natalizumab.&#xD;
&#xD;
               -  Interferon therapy within 8 weeks prior to baseline.&#xD;
&#xD;
               -  Prior treatment with lymphocyte depleting therapies and alkylating agents.&#xD;
&#xD;
               -  Received selective B lymphocyte depleting agents within 1 year prior to baseline.&#xD;
&#xD;
               -  Receiving leukocyte apheresis, granulocyte apheresis, or plasma exchange within 6&#xD;
                  months of baseline.&#xD;
&#xD;
               -  JAK inhibitors within 3 months prior to baseline.&#xD;
&#xD;
               -  Any investigational procedures(s) or product(s)30 days prior to baseline.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin induced thrombocytopenia&#xD;
&#xD;
          -  Known history of hypersensitivity, intolerance, or allergic reaction to PF-06687234 or&#xD;
             any constituent of the IP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dothan Surgery Center</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gut PC, dba Digestive Health Specialists of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Investigational Drug Services</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevy Chase Endoscopy Center</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGG Group Co., Inc., Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Endoscopy</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastside Endoscopy Center</name>
      <address>
        <city>Macomb</city>
        <state>Michigan</state>
        <zip>48044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastside Endoscopy Center</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health-Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John Of God Health Care Inc. Trading as St. John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Montlegia</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Rhodense - Ospedale di Circolo di Rho</name>
      <address>
        <city>Rho</city>
        <state>Milano</state>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>22252</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah International Medical Research Center</name>
      <address>
        <city>Riyadh</city>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11472</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC &quot;Dr Dragisa Misovic-Dedinje&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara - Clinic for Gastroenterology and Hepatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Mersin</city>
        <zip>33110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7581002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 4, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

